Managing and Investigational Treatments

Because Mitchell Syndrome was only identified in 2020, there is not yet a “gold standard” or FDA-approved treatment protocol ^[1][2]. However, understanding that the disease is caused by an overactive enzyme—rather than a missing one—has completely changed how researchers and doctors approach care ^[3][1].

A Different Approach to Treatment

If your child was initially thought to have recessive ACOX1 deficiency, the goal might have been to lower very-long-chain fatty acids (VLCFAs). In Mitchell Syndrome, however, reducing VLCFAs is not the primary goal because the mutation actually makes the enzyme work too hard, creating toxic levels of hydrogen peroxide ^[3][1]. In fact, some children with severe Mitchell Syndrome have completely normal VLCFA levels ^[4][2].

Investigational treatments instead focus on neutralizing the oxidative stress and managing the resulting inflammation ^[3][5]. It is crucial to understand that the therapies listed below are highly experimental. They are based on laboratory models and a very small number of uncontrolled human case reports.

Antioxidant Therapies

An area of investigational research involves antioxidants, which act like a “sponge” to soak up the excess hydrogen peroxide produced by the mutated enzyme ^[3].

• Topical N-acetylcysteine (NAC): For the severe scaly skin (ichthyosis) associated with the syndrome, a topical form of NAC (sometimes in a 10% concentration) has been used in investigational settings ^[2][4]. In one report, two children saw significant improvement, with one achieving complete skin recovery after three months of consistent use ^[2]. Warning: Formulations and concentrations are not standardized. You should never attempt to compound topical NAC at home or use over-the-counter NAC products without your treating team’s explicit plan, as this can cause severe skin irritation, infection, or dangerous drug interactions.
• Systemic NAC and NACA: Some children have been treated with oral N-acetylcysteine (NAC) or a newer version called N-acetylcysteine amide (NACA) ^[6][4]. While these are not cures, case reports have noted broad improvements in overall condition and specific symptoms like eye health ^[6][4].
• Preclinical Success: In laboratory studies using fruit flies and zebrafish with the Mitchell mutation, antioxidants were able to stop nerve damage and restore the ability to move and swim ^[1][3].

Immunoglobulin Therapy (IVIG)

Some doctors have added Intravenous Immunoglobulin (IVIG) to the treatment plan to address the inflammatory part of the disease ^[5].

• Case Evidence: One case report described a 10-year-old child who had lost the ability to walk. After one year of a combined regimen—monthly IVIG plus antioxidant therapy—the child regained the ability to walk, run, and jump ^[5].
• A Note on Combination and Risks: Because these treatments are often given together, it is difficult for researchers to know exactly which part of the therapy is responsible for the improvement ^[5]. Furthermore, IVIG carries serious potential risks, including infusion reactions, thrombosis (blood clots), kidney injury, and aseptic meningitis.

Advocating Safely

Since Mitchell Syndrome is so rare, you may find yourself in the position of sharing recent research with your medical team. Current disease-directed management is often “off-label,” meaning doctors use medications in ways not yet officially approved for this specific condition ^[5][7].

Key areas for advocacy and discussion with your care team include:

• Targeting the Mechanism: Discussing whether treatments targeting oxidative stress and glial damage are appropriate for your child ^[3][1].
• Multidisciplinary Monitoring: Coordinating between neurology, dermatology, and metabolic specialists to track progress across all symptom areas ^[5][2].
• Specialized Centers: Seeking out neurogenetics or metabolic centers that are familiar with the latest Mitchell Syndrome research and may offer access to clinical trials or emerging antioxidant therapies ^[5][7].

While the path is still being built, the recovery of motor function seen in some case reports offers a focus for ongoing research ^[5][6]. Always work with your team to define clear goals before starting an experimental treatment: how will improvement be measured, how long will the trial last, and what side effects mean the treatment must be stopped.